JP2006515620A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006515620A5 JP2006515620A5 JP2006500813A JP2006500813A JP2006515620A5 JP 2006515620 A5 JP2006515620 A5 JP 2006515620A5 JP 2006500813 A JP2006500813 A JP 2006500813A JP 2006500813 A JP2006500813 A JP 2006500813A JP 2006515620 A5 JP2006515620 A5 JP 2006515620A5
- Authority
- JP
- Japan
- Prior art keywords
- insulin
- use according
- medicament
- oral administration
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 86
- 102000004877 Insulin Human genes 0.000 claims 41
- 108090001061 Insulin Proteins 0.000 claims 41
- 229940125396 insulin Drugs 0.000 claims 41
- 239000003814 drug Substances 0.000 claims 17
- 241000124008 Mammalia Species 0.000 claims 15
- 206010012601 diabetes mellitus Diseases 0.000 claims 10
- 238000004519 manufacturing process Methods 0.000 claims 8
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 claims 6
- 108010075254 C-Peptide Proteins 0.000 claims 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 6
- 208000002705 Glucose Intolerance Diseases 0.000 claims 6
- 239000008103 glucose Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 201000009104 prediabetes syndrome Diseases 0.000 claims 6
- UQFYDAAKCZKDHS-UHFFFAOYSA-M sodium;4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate Chemical compound [Na+].OC1=CC(Cl)=CC=C1C(=O)NCCCC([O-])=O UQFYDAAKCZKDHS-UHFFFAOYSA-M 0.000 claims 6
- 241000282414 Homo sapiens Species 0.000 claims 5
- 210000004369 blood Anatomy 0.000 claims 5
- 239000008280 blood Substances 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 238000010521 absorption reaction Methods 0.000 claims 4
- 230000007423 decrease Effects 0.000 claims 4
- 229940124447 delivery agent Drugs 0.000 claims 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 1
- 241000283073 Equus caballus Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 241000009328 Perro Species 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 229940125395 oral insulin Drugs 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 210000003240 portal vein Anatomy 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43819503P | 2003-01-06 | 2003-01-06 | |
| US43845103P | 2003-01-06 | 2003-01-06 | |
| US60/438,195 | 2003-01-06 | ||
| US60/438,451 | 2003-01-06 | ||
| US47896703P | 2003-06-16 | 2003-06-16 | |
| US60/478,967 | 2003-06-16 | ||
| PCT/US2004/000273 WO2004062587A2 (en) | 2003-01-06 | 2004-01-06 | Night-time oral insulin therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006515620A JP2006515620A (ja) | 2006-06-01 |
| JP2006515620A5 true JP2006515620A5 (https=) | 2007-03-01 |
| JP5452843B2 JP5452843B2 (ja) | 2014-03-26 |
Family
ID=32719186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006500813A Expired - Fee Related JP5452843B2 (ja) | 2003-01-06 | 2004-01-06 | 夜間の経口インスリン治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7384914B2 (https=) |
| EP (1) | EP1592438B1 (https=) |
| JP (1) | JP5452843B2 (https=) |
| AU (1) | AU2004204727B8 (https=) |
| CA (1) | CA2511530C (https=) |
| ES (1) | ES2465496T3 (https=) |
| NZ (1) | NZ541058A (https=) |
| WO (1) | WO2004062587A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1332711C (zh) | 2002-02-20 | 2007-08-22 | 埃米球科技有限公司 | 施用glp-1分子的方法 |
| WO2004080401A2 (en) * | 2003-03-06 | 2004-09-23 | Emisphere Technologies, Inc. | Oral insulin therapies and protocol |
| US20050203001A1 (en) | 2004-03-05 | 2005-09-15 | Emisphere Technologies, Inc. | Oral insulin therapies and protocol |
| US20060286129A1 (en) | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
| NZ551196A (en) * | 2004-05-14 | 2010-08-27 | Emisphere Tech Inc | Compounds and compositions for delivering active agents |
| AU2005244985B2 (en) | 2004-05-19 | 2011-09-01 | Emisphere Technologies, Inc. | Acyclovir formulations |
| CN101014360A (zh) * | 2004-08-03 | 2007-08-08 | 埃米斯菲尔技术公司 | 抗糖尿病口服胰岛素-双胍组合物 |
| WO2006072070A2 (en) | 2004-12-29 | 2006-07-06 | Emisphere Technologies, Inc. | Pharmaceutical formulations of gallium salts |
| WO2006076692A1 (en) | 2005-01-12 | 2006-07-20 | Emisphere Technologies, Inc. | Compositions for buccal delivery of parathyroid hormone |
| JP2008542235A (ja) * | 2005-05-25 | 2008-11-27 | ノボ・ノルデイスク・エー/エス | 安定化ポリペプチド製剤 |
| US8097584B2 (en) * | 2005-05-25 | 2012-01-17 | Novo Nordisk A/S | Stabilized formulations of insulin that comprise ethylenediamine |
| WO2007121318A2 (en) | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| US8771712B2 (en) | 2006-05-09 | 2014-07-08 | Emisphere Technologies, Inc. | Topical administration of acyclovir |
| JP5475443B2 (ja) | 2006-06-28 | 2014-04-16 | エミスフェアー・テクノロジーズ・インク | 硝酸ガリウム製剤 |
| WO2008132731A2 (en) * | 2007-04-26 | 2008-11-06 | Oramed Pharmaceuticals, Inc | Methods and compositions for rectal administration of insulin |
| IL188647A0 (en) * | 2008-01-08 | 2008-11-03 | Orina Gribova | Adaptable structured drug and supplements administration system (for oral and/or transdermal applications) |
| RU2494755C2 (ru) | 2008-08-18 | 2013-10-10 | Интера Био Лтд. | Способы и композиции для перорального введения белков |
| CA2767342C (en) | 2009-07-09 | 2018-05-01 | Oshadi Drug Administration Ltd. | Matrix carrier compositions, methods and uses |
| EP2461803B1 (en) | 2009-08-03 | 2018-10-17 | Emisphere Technologies, Inc. | Fast-acting naproxen composition with reduced gastrointestinal effects |
| US20240315972A1 (en) | 2021-07-12 | 2024-09-26 | Zidkiyahu Simenhaus | Protein containing bio-active compositions comprising cellulose microparticle carriers |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863896A (en) | 1984-05-03 | 1989-09-05 | Technology Unlimited, Inc. | Diabetic control by combined insulin forms |
| RU2066551C1 (ru) | 1994-03-23 | 1996-09-20 | Институт нефтехимического синтеза РАН | Способ получения инсулинсодержащих полимерных гидрогелей |
| US5780243A (en) * | 1996-06-28 | 1998-07-14 | Thaco Research, Ltd. | Methods for the quantitative analysis of organic compounds |
| SE520392C2 (sv) * | 1996-09-27 | 2003-07-01 | Creative Peptides Sweden Ab C | Specifika peptider för behandling av diabetes mellitus |
| US6197340B1 (en) * | 1998-05-28 | 2001-03-06 | Medical Research Institute | Controlled release lipoic acid |
| US7227033B2 (en) * | 2002-01-09 | 2007-06-05 | Emisphere Technologies, Inc. | Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate |
| JP2004521857A (ja) * | 2000-06-29 | 2004-07-22 | エミスフェアー・テクノロジーズ・インク | 活性剤の送達のための化合物及び組成物 |
| NZ524138A (en) * | 2000-09-06 | 2004-12-24 | Emisphere Tech Inc | Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents |
| US20020147135A1 (en) * | 2000-12-21 | 2002-10-10 | Oliver Schnell | Method and device for producing an adapted travel treatment plan for administering a medicine in the event of a long-haul journey |
| US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
| US6828297B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US20030198666A1 (en) * | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| US7137951B2 (en) * | 2002-10-23 | 2006-11-21 | Joseph Pilarski | Method of food and insulin dose management for a diabetic subject |
| NZ551196A (en) | 2004-05-14 | 2010-08-27 | Emisphere Tech Inc | Compounds and compositions for delivering active agents |
-
2004
- 2004-01-06 CA CA2511530A patent/CA2511530C/en not_active Expired - Fee Related
- 2004-01-06 US US10/541,433 patent/US7384914B2/en not_active Expired - Lifetime
- 2004-01-06 EP EP04700388.4A patent/EP1592438B1/en not_active Expired - Lifetime
- 2004-01-06 NZ NZ541058A patent/NZ541058A/en not_active IP Right Cessation
- 2004-01-06 JP JP2006500813A patent/JP5452843B2/ja not_active Expired - Fee Related
- 2004-01-06 ES ES04700388.4T patent/ES2465496T3/es not_active Expired - Lifetime
- 2004-01-06 AU AU2004204727A patent/AU2004204727B8/en not_active Ceased
- 2004-01-06 WO PCT/US2004/000273 patent/WO2004062587A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006515620A5 (https=) | ||
| Langoth et al. | Thiolated Chitosans: Design and In Vivo Evaluation of a Mucoadhesive Buccal Peptide Drug Delivery System: Langoth et al. | |
| US10130684B2 (en) | Oral dissolving films for insulin administration, for treating diabetes | |
| US20160346288A1 (en) | 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal | |
| KR20070116946A (ko) | 당뇨 치료에서의 혈중 포도당의 우수한 조절 | |
| WO2009048945A1 (en) | Rapid mucosal gel or film insulin compositions | |
| US20240238374A1 (en) | Methods and compositions for inducing brown adipogenesis | |
| JP7444786B2 (ja) | 低用量の安定なグルカゴンを使用する肥満治療手術後の低血糖症の処置 | |
| JP2008509145A (ja) | 抗糖尿病性経口インスリン−ビグアニドの組み合わせ | |
| US20210379059A1 (en) | Combination of substances for regenerative therapy in patients with type 1 diabetes mellitus | |
| US20130096048A1 (en) | Treatment of sepsis and septic shock using ghrelin and growth hormone | |
| JPH07556B2 (ja) | 間質性膀胱炎に対する治療用医薬組成物 | |
| RU2371195C2 (ru) | Способ лечения вирусных инфекций | |
| AU2018329496A1 (en) | Sublingual epinephrine tablets | |
| Pozzilli et al. | A 2-year pilot trial of continuous subcutaneous insulin infusion versus intensive insulin therapy in patients with newly diagnosed type 1 diabetes (IMDIAB 8) | |
| JP2012532852A (ja) | 2型糖尿病における食後高血糖の経頬粘膜治療の方法、および当該治療に用いられる医薬組成物 | |
| JP2021506933A (ja) | 1型糖尿病およびインスリン使用2型糖尿病における運動誘発性低血糖の処置 | |
| Nzerue et al. | Use of octreotide to treat prolonged sulfonylurea-induced hypoglycemia in a patient with chronic renal failure | |
| CN101217960B (zh) | 用于改善尿毒症的治疗药和处置方法 | |
| CN110169976A (zh) | 含有腺苷a1受体激动剂的抗抑郁药物组合物及其应用 | |
| CN105663152A (zh) | 三乙酰基-3-羟基苯基腺苷在制备改善胰岛素抵抗及相关疾病中的应用 | |
| CN1346278A (zh) | 麻醉的调节 | |
| JP2006519881A5 (https=) | ||
| Kumbhar et al. | Novel route of inhaled insulin for diabetes treatment | |
| EP4631499A1 (en) | Delayed timed release pharmaceutical composition, preparation method therefor, and use thereof |